UNICREDIT BANK/CALL/VERTEX PHARMACEUTICALS/550/0.1/15.01.25 | Real-time BOERSE MUENCHEN 07:42:09 2024-05-23 EDT | ||
| 1.17 EUR | 0.00% |
|
| Current month | +105.26% | ||
| 1 month | +42.68% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 1.17 | 0.00% |
| 24-05-22 | 1.17 | +7.34% |
| 24-05-21 | 1.09 | -18.05% |
| 24-05-20 | 1.33 | +12.71% |
| 24-05-17 | 1.18 | +5.36% |
Real-time BOERSE MUENCHEN
Last update May 23, 2024 at 07:42 am
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
UniCredit
|
| WKN | HC620S |
| ISIN | DE000HC620S7 |
| Date issued | 2023-04-14 |
| Strike | 550 $ |
| Maturity | 2025-01-15 (237 Days) |
| Parity | 10 : 1 |
| Emission price | 1.53 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.75 € |
|---|---|
| Lowest since issue | 0.53 € |
| Spread | 0.1 € |
| Spread % | 8.13% |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
447.5
USD
Average target price
462.8
USD
Spread / Average Target
+3.41%
- Stock Market
- Warrants
- Warrant
